Zydus Cadila's Net Profit up by 41% in Q2

 
For the second quarter ended September 30, 2015, Zydus Cadila reported Total Operating Income of Rs. 2460 crores, up by 17% from Rs. 2108 crores in the corresponding quarter of the previous year on a consolidated basis. Net Profit for the same period was up by 41% from
Rs. 278 crores to Rs. 391 crores.

During the quarter, the company's business in the US posted sales of Rs. 1004 crores registering a growth of 25%. The company received approval for 1 new product from the USFDA and 2 products were launched in the US market.

In the domestic formulations market, the company launched 13 new products, including line extensions, of which 4 products were the first to be launched in India. In Mexico, the company launched 2 new products during the quarter, taking the cumulative launches to over 15 and received the regulatory approval for 6 more dossiers, taking the cumulative number of approvals to over 30.

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.